Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (24)

1

Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015) : an open-label, randomised, Phase 3 trial

enthalten in: British journal of cancer | 2024

von Jo, J. | Kim, Y. | Choi, H. | +17

ErratumIn: Br J Cancer. 2023 Dec 4;:. - PMID 38049557

2

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer : final results of the JFMC37-0801 study

enthalten in: British journal of cancer | 2019

von Tomita, N. | Kunieda, K. | Maeda, A. | +14

3

Immune gene expression and response to chemotherapy in advanced breast cancer

enthalten in: British journal of cancer | 2018

von Foukakis, T. | Lövrot, J. | Matikas, A. | +14

4

Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation : an individual patient data meta-analysis of two phase 3 trials

enthalten in: British journal of cancer | 2017

von Goey, K. | Elias, S. | Hinke, A. | +5

5

Long-term results and recurrence patterns from SCOPE-1 : a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer

enthalten in: British journal of cancer | 2017

von Crosby, T. | Hurt, C. | Falk, S. | +11

6

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study

enthalten in: British journal of cancer | 2016

von Pugh, S. | Bowers, M. | Ball, A. | +20

7

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

enthalten in: British journal of cancer | 2016

von Zielinski, C. | Lang, I. | Beslija, S. | +7

8

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

enthalten in: British journal of cancer | 2015

von Lim, S. | Kim, T. | Hong, Y. | +14

9

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

enthalten in: British journal of cancer | 2015

von Weickhardt, A. | Williams, D. | Lee, C. | +12

10

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

enthalten in: British journal of cancer | 2015

von Price, T. | Bruhn, M. | Lee, C. | +12